Promising Research and Thymalin

The Role of Nonathymulin Peptide in Cancer Patients

According to a preliminary rodent study, Thymalin peptide may strongly complement pulsed laser radiation for treating some types of cancer.^[1] Thymalin can boost antibody-producing cells in the spleen and can be used to improve the benefits of pulsed laser radiation.

Nonathymulin peptide has been shown in studies to have anti-tumor properties, slowing tumor development in almost 80% of instances and decreasing tumor size in nearly half of animals.^[2] The scientists report that “High efficiency of Thymalin can be attributed to the use of lower doses of the substance and their modulation during the treatment course in accordance with the regimes of activation therapy.” As a result, using Thymalin in conjunction with pulsed laser light is unnecessary.

Thymalin peptide combined with plasmapheresis is more effective in combating chronic lympholeukemia.^[3] Furthermore, it can develop hematological compensation than traditional chemotherapy therapies. The therapy also improves lymphoid function.^[4] 

Immune Function

Thymalin may affect cellular immunity, modifying lymphocyte subpopulation levels, influencing T-cell development, and modulating natural killer (NK) cell activity, according to research.^[5]

Nonathymulin peptide treatment can correct the immune system and improve T-lymphocyte proliferation in diabetic retinopathy patients, resulting in less inflammation and slower disease progression rates.^[6] This might apply to chronic immunological deficiency/immune HIV dysregulation. Thymalin, in combination with HAART, may repair immune system damage and increase CD4 + T-cell counts in HIV patients.

Research is ongoing to see whether Thymalin can be added to HIV vaccinations to boost immunization responses. Thymalin peptide treatment in mice without the thyroid gland reverses or protects the animals from weight loss and cell growth. 

The Effects of Thymalin Peptide on Kidney Diseases

Nonathymulin peptide administration has been shown in clinical research to assist individuals with inflammatory kidney disease, such as chronic glomerulonephritis.

The Effect of Thymalin Peptide on Tuberculosis

Patients with severe pulmonary tuberculosis were grouped according to studies. The conventional tuberculosis treatment regimen was given to one group, whereas antibiotic therapy plus Thymalin peptide to the other. The group given Thymalin additive had higher cure rates than the other group. Thymalin, when used with conventional antibiotic treatment, has a cure rate of around 95%.

Patients with severe tuberculosis have low cellular immunity, as measured by T-cell levels. The T-cell decrease is detrimental if these people have an immunosuppressive condition such as diabetes.

The Role of Thymalin Peptide in Circadian-Rhythm

Circadian rhythm disruptions are due to alterations in thymic components and cellular and humoral immunity, according to research. Changes in circadian rhythm, according to scientists, can affect thymic function, leading to immune system suppression. Thymalin, on the other hand, does not regulate circadian rhythm. However, it can reset alterations in immunological insufficiency induced by variations in sleep-wake cycles. 

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

References

1. Kozlov, A. P., & Moskalik, K. G. (1980). Pulsed laser radiation therapy of skin tumors. Cancer, 46(10), 2172–2178. doi:10.1002/1097-0142(19801115)46:10‹2172::aid-cncr2820461013›3.0.co;2-l.
2. Zhukova, G. V., Schikhlyarova, A. I., Barteneva, T. A., Shevchenko, A. N., & Zakharyuta, F. M. (2018). Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo. Bulletin of experimental biology and medicine, 165(1), 80–83. doi:10.1007/s10517-018-4104-z.
3. Tretiak, N. N., Babenko, T. F., Gaĭdukova, S. N., Zverkova, A. S., & Beschastnaia, S. P. (1998). Effektivnost’ primeneniia timalina i plazmafereza v kompleksnom lechenii bol’nykh khronicheskim limfoleĭkozom [The efficacy of using thymalin and plasmapheresis in the combined treatment of patients with chronic lympholeukemia]. Likars’ka sprava, (2), 93–96.
4. Babenko, T. F., Antonenko, V. T., & SkuratovskiUi, M. F. (1989). Timalin v kompleksnom lechenii bol’nykh khronicheskim limfoleĭkozom [Thymalin in the combined treatment of patients with chronic lympholeukemia]. Vrachebnoe delo, (3), 47–49.
5. Bach, J., Bardenne, M., Pleau, J., & Rosa, J. (1977). Biochemical characterisation of a serum thymic factor. Nature, 266(5597), 55–57. doi:10.1038/266055a0.
6. Zhaboiedov, H. D., Bychkova, N. H., Skrypnik, R. L., & Sydorova, M. V. (2001). Doslidzhennia stanu klitynnoho i humoral’noho imunitetu ta vyznachennia indyvidual’noï chutlyvosti T-limfotsytiv do imunokorektoriv u khvorykh s diabetychnoiu retynopatiieiu [Evaluation of cellular and humoral immunity and individual sensitivity of T-lymphocytes to immunocorrectors in patients with diabetic retinopathy]. Likars’ka sprava, (1), 53–56.
7. Isaeva, M. P., Budazhabon, G. B., & Kuznik, B. I. (1989). Vliianie timalina na pokazateli immuniteta i gemostaza u bol’nykh rasprostranennymi formami psoziaza [The effect of thymalin on indices of immunity and hemostasis in patients with disseminated forms of psoriasis]. Vestnik dermatologii i venerologii, (10), 42–43.
8. Budazhabon, G. V., Kuznik, B. I., Morozov, V. G., Orlova, N. N., & Khavinson, V. K.h (1984). Sostoianie immunogeneza i gemostaza u bol’nykh s obostreniem khronicheskogo glomerulonefrita, lechennykh timalinom [Immunogenesis and hemostasis in patients with exacerbated chronic glomerulonephritis treated with thymalin]. Terapevticheskii arkhiv, 56(10), 62–66.
9. Maslennikov, A. A., Kamenev, V. F., & Kolomiets, V. M. (2007). Problemy tuberkuleza i boleznei legkikh, (9), 30–33.